3KHOYNEZHAD A. Promising aspects and caveats of stud- ies on anti-apoptotic therapies in patients with heart failure [J]. EurJHeartFail, 2007, 9(2): 120-123.
2[2]Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives[J]. Clin Physiol,2001,21(6):661～72.
3[4]Kang YJ. Molecular and cellular mechanisms of cardiotoxicity[J].Environ Health Perspect,2001,109(Suppl)1:27～34.
4钱学肾.现代心血管病学[M].北京:人民军医出版社,1999.860-861.
5陈敏章 邵丙扬 王海燕 等.中华内科学[M].北京：人民卫生出版社,1999.2502.
6刘延龄 熊鉴然主编.临床超声心动图学[M].北京：科学出版社,2001.614.
7Miyamae M,Camacho SA,Weiner MW,et al.Attenuation of postischemic reperfusion injury is related to prevention of [ Ca2+] m overload in rat hearts.Am J Physiol,1996,271:H2145-2153.
9Flameng W,Borgers M,Daenen W,et al.Ultrastructural and cytochemical correlates of myocardial protection by cardiac hypothermia in man.J Thorac Cardiovasc Surg,1980,79:413-424.
10Kaneko M,Matsumoto Y,Hayashi H,et al.Oxygen free radicals and calcium homeostasis in heart.Mol Cell Biochem,1994,135:99-105.
1Loh JP, Pendyala LK, Kitabata H, et al. Comparison of outcomes after percutaneous Coronary intervention among different coronary subsets(stable and unstable angina pectoris and ST-segment and non-ST-segment myocardial Infarction)[J]. Am J Cardiol,2014, 113(11):1794-1801.
2陈灏珠.实用内科学[M].北京:人民卫生出版社,2002:1373.
3Das MK,Zipes DP. Anti-arrhythmic and non-anti-arrhythmic drugs for sudden cardiac death prevention [J]. J Cardio-vasic Phannacol, 2010,55 (5):438-449.
4Ravens U. Novel pharmaeologieal approaehes for anti-arrhythmic therapy[J]. Naunyn Schmiede-bergs Arch Pharmaeol, 2010,381 (3):187-193.
5Baguet JP, Chavanon O, Sessa C, et al. European Society of Hy-pertension scientific news letter:hypertension and aortic diseases [J]. J Hypertens,2012,30(2):440-443.
6Thrumurthy SG, Karthikesalingam A, Patterson BO, et al. The di-agnosis and management of aortic dissection[J]. BMJ,2011,344 (5):8290.
